首页> 美国卫生研究院文献>Springer Open Choice >Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes
【2h】

Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes

机译:区分新合成大麻素FUBIMINA(BIM-2201)摄入与其异构体THJ-2201的策略:FUBIMINA在人肝细胞中的代谢

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since 2013, a new drugs-of-abuse trend attempts to bypass drug legislation by marketing isomers of scheduled synthetic cannabinoids (SCs), e.g., FUBIMINA (BIM-2201) and THJ-2201. It is much more challenging to confirm a specific isomer’s intake and distinguish it from its structural analog because the isomers and their major metabolites usually have identical molecular weights and display the same product ions. Here, we investigated isomers FUBIMINA and THJ-2201 and propose strategies to distinguish their consumption. THJ-2201 was scheduled in the US, Japan, and Europe; however, FUBIMINA is easily available on the Internet. We previously investigated THJ-2201 metabolism in human hepatocytes, but human FUBIMINA metabolism is unknown. We aim to characterize FUBIMINA metabolism in human hepatocytes, recommend optimal metabolites to confirm its consumption, and propose strategies to distinguish between intakes of FUBIMINA and THJ-2201. FUBIMINA (10 μM) was incubated in human hepatocytes for 3 h, and metabolites were characterized with high-resolution mass spectrometry (HR-MS). We identified 35 metabolites generated by oxidative defluorination, further carboxylation, hydroxylation, dihydrodiol formation, glucuronidation, and their combinations. We recommend 5′-OH-BIM-018 (M34), BIM-018 pentanoic acid (M33), and BIM-018 pentanoic acid dihydrodiol (M7) as FUBIMINA specific metabolites. THJ-2201 produced specific metabolite markers 5′-OH-THJ-018 (F26), THJ-018 pentanoic acid (F25), and hydroxylated THJ-2201 (F13). Optimized chromatographic conditions to achieve different retention times and careful selection of specific product ion spectra enabled differentiation of isomeric metabolites, in this case FUBIMINA from THJ-2201. Our HR-MS approach should be applicable for differentiating future isomeric SCs, which is especially important when different isomers have different legal status.
机译:自2013年以来,一种新的滥用药物趋势试图通过销售预定的合成大麻素(SCs)异构体(例如FUBIMINA(BIM-2201)和THJ-2201)来绕开药物立法。确认特定异构体的摄入量并将其与结构类似物区分开来更具挑战性,因为这些异构体及其主要代谢物通常具有相同的分子量并显示相同的产物离子。在这里,我们研究了异构体FUBIMINA和THJ-2201并提出了区分其消费量的策略。 THJ-2201计划在美国,日本和欧洲上市;但是,FUBIMINA可以从Internet上轻松获得。我们先前调查了人类肝细胞中THJ-2201的代谢,但人类FUBIMINA的代谢尚不清楚。我们旨在表征人肝细胞中的FUBIMINA代谢特征,推荐最佳代谢物以确认其消耗,并提出区分FUBIMINA和THJ-2201摄入量的策略。将FUBIMINA(10μM)在人肝细胞中孵育3小时,并通过高分辨率质谱(HR-MS)对代谢产物进行表征。我们确定了由氧化脱氟,进一步羧化,羟基化,二氢二醇形成,葡萄糖醛酸化及其组合产生的35种代谢产物。我们建议使用5'-OH-BIM-018(M34),BIM-018戊酸(M33)和BIM-018戊酸二氢二醇(M7)作为FUBIMINA特定代谢物。 THJ-2201产生了特定的代谢物标记物5'-OH-THJ-018(F26),THJ-018戊酸(F25)和羟基化THJ-2201(F13)。优化的色谱条件以实现不同的保留时间,并仔细选择特定的产物离子质谱图,可以区分异构体代谢产物,在这种情况下为THB-2201的FUBIMINA。我们的HR-MS方法应适用于区分未来的异构体SC,这在不同异构体具有不同法律地位时尤其重要。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号